HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.

AuthorsM Okamoto, A Okano, S Akamatsu, E Ashihara, T Inaba, H Takenaka, N Katoh, S Kishimoto, C Shimazaki
JournalLeukemia (Leukemia) Vol. 20 Issue 1 Pg. 172-3 (Jan 2006) ISSN: 0887-6924 [Print] England
PMID16239908 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Steroids
  • Rituximab
Topics
  • Adult
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Fatal Outcome
  • Female
  • Graft vs Host Disease (complications, drug therapy, pathology)
  • Humans
  • Male
  • Risk Factors
  • Rituximab
  • Scleroderma, Systemic (complications, drug therapy, pathology)
  • Steroids (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: